HTA V.2.0 was used for gene expression profiling to allow analysis of coding as well as non-coding and alternatively spliced transcripts in peripheral T cells isolated from patients with melanoma treated with anti-PD-1, anti-CTLA-4, and combinations of both antibodies. The gene discussed is CTLA4; the disease is melanoma.